Sunday December 8, 2019

Using Marijuana can Help in the Treatment of Drug Addiction and Depression: Study

Cannabis use might not be recommended for conditions such as bipolar disorder and psychosis

0
//
Marijuana. Pixabay

Toronto, November 16, 2016: Using marijuana could help some alcoholics and people addicted to opioids kick the habit and may also help people suffering from depression, post-traumatic stress disorder (PTSD) and social anxiety, says a study.

NewsGram brings to you current foreign news from all over the world.

“Research suggests that people may be using cannabis as an exit drug to reduce the use of substances that are potentially more harmful, such as opioid pain medication,” said the study’s lead investigator Zach Walsh, Associate Professor at University of British Columbia’s Okanagan campus in Canada.

The study published in the journal Clinical Psychology Review is based on a systematic review of research on the medical cannabis use and mental health as well as reviews on non-medical cannabis use.

NewsGram brings to you top news around the world today.

However, the review concluded that cannabis use might not be recommended for conditions such as bipolar disorder and psychosis.

“In reviewing the limited evidence on medical cannabis, it appears that patients and others who have advocated for cannabis as a tool for harm reduction and mental health have some valid points,” Walsh said.

Check out NewsGram for latest international news updates.

It is important to identify ways to help mental health professional move beyond stigma to better understand the risk and benefits of cannabis, Walsh added.

“There is not currently a lot of clear guidance on how mental health professionals can best work with people who are using cannabis for medical purposes,” Walsh said. (IANS)

Next Story

Research Finds That Drug Can Curb Dementia’s Delusions

About 8 million Americans have dementia, and studies suggest that up to 30% of them develop psychosis.

0
Television actor Barbara Windsor and her husband Scott Mitchell talks about Drugs
Television actor Barbara Windsor and her husband Scott Mitchell pose with a placard in front of Downing Street ahead of a meeting with Britain's Prime Minister Boris Johnson in London, Britain. VOA

A drug that curbs delusions in Parkinson’s patients did the same for people with Alzheimer’s disease and other forms of dementia in a study that was stopped early because the benefit seemed clear.

If regulators agree, the drug could become the first treatment specifically for dementia-related psychosis and the first new medicine for Alzheimer’s in nearly two decades. It targets some of the most troubling symptoms that patients and caregivers face — hallucinations that often lead to anxiety, aggression, and physical and verbal abuse.

Results were disclosed Wednesday at a conference in San Diego.

Unmet need for treatment

“This would be a very important advance,” said one independent expert, Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation.

Although the field is focused on finding a cure for dementia and preventing future cases, “there is a huge unmet need for better treatment” for those who have it now, said Maria Carrillo, the Alzheimer’s Association’s chief science officer.

The drug is pimavanserin, a daily pill sold as Nuplazid by Acadia Pharmaceuticals Inc. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions.

Dementia Drugs
Dementia is a syndrome in which there is deterioration in memory, thinking, behaviour and the ability to perform everyday activities. Pixabay

About 8 million Americans have dementia, and studies suggest that up to 30% of them develop psychosis.

“It’s terrifying,” said Dr. Jeffrey Cummings of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. “You believe that people might be trying to hurt you. You believe that people are stealing from you. You believe that your spouse is unfaithful to you. Those are the three most common false beliefs.”

How the study worked

He consults for Acadia and helped lead the study, which included about 400 people with dementia and psychosis. All were given a low dose of the drug for three months, and those who seemed to respond or benefit were then split into two groups. Half continued on the drug and the others were given dummy pills for six months or until they had a relapse or worsening of symptoms. Neither the patients nor their doctors knew who was getting what.

Independent monitors stopped the study when they saw that those on dummy pills were more than twice as likely as those on the drug to relapse or worsen — 28% versus nearly 13%.

There were relatively few serious side effects — 5% in the drug group and 4% in the others. Headaches and urinary tract infections were more common among those on the drug. Two deaths occurred, but study leaders said neither was related to the drug.

The drug could become the first treatment for dementia
The drug could become the first treatment specifically for dementia-related psychosis. Pixabay

Carrillo said the study was small, but the drug’s effect seemed large, and it’s not known whether the federal Food and Drug Administration would want more evidence to approve a new use.

Risk of death

Current anti-psychotic medicines have some major drawbacks and are not approved for dementia patients.

“They’re often used off label because we have very few other options,” Fillit said.

ALSO READ: Researchers Associate Social Media Use to Eating Disorder in Adolescents

All carry warnings that they can raise the risk of death in elderly patients, as does Nuplazid.

Cost could be an issue — about $3,000 a month. What patients pay can vary depending on insurance coverage. (VOA)